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Summary Background IMGN901 is a CD56-targeting anti-
body-drug conjugate designed for tumor-selective delivery of
the cytotoxic maytansinoid DM1. This phase 1 study investi-
gated the safety, tolerability, pharmacokinetics, and prelimi-
nary activity of IMGN901 in patients with CD56-expressing
solid tumors. Methods Patients were enrolled in cohorts of
escalating IMGN901 doses, administered intravenously, on 3
consecutive days every 21 days. A dose-expansion phase ac-
crued patients with small cell lung cancer (SCLC),Merkel cell
carcinoma (MCC), or ovarian cancer. Results Fifty-two pa-
tients were treated at doses escalating from 4 to 94 mg/m2/
day. The maximum tolerated dose (MTD) was determined to
be 75 mg/m2. Dose-limiting toxicities included fatigue, neu-
ropathy, headache or meningitis-like symptoms, chest pain,
dyspnea, and myalgias. In the dose-expansion phase
(n = 45), seven patients received 75 mg/m2 and 38 received
60mg/m2 for up to 21 cycles. The recommended phase 2 dose
(RP2D) was established at 60 mg/m2 during dose expansion.
Overall, treatment-emergent adverse events (TEAEs) were
experienced by 96.9 % of all patients, the majority of which
were Grade 1 or 2. The most commonly reported Grade 3 or 4
TEAEs were hyponatremia and dyspnea (each 8.2 %).
Responses included 1 complete response (CR), 1 clinical
CR, and 1 unconfirmed partial response (PR) in MCC; and
1 unconfirmed PR in SCLC. Stable disease was seen for 25 %
of all evaluable patients who received doses ≥60 mg/m2.
Conclusions The RP2D for IMGN901 of 60 mg/m2 adminis-
tered for 3 consecutive days every 3 weeks was associated
with an acceptable tolerability profile. Objective responses
were observed in patients with advanced CD56+ cancers.
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Introduction
The glycoprotein CD56, also known as NCAM1, is a member
of the neural cell adhesion molecule family [1] that plays
important functional roles during development, nervous sys-
tem differentiation, and immune surveillance [2]. Primarily
expressed in neuroendocrine, natural killer, and Tcell lineages
[3], aberrant CD56 expression is seen in a variety of hemato-
logical malignancies (e.g. multiple myeloma, myelocytic and
lymphocytic leukemia) as well as solid tumors (most notably
small cell lung cancer [SCLC],Merkel cell carcinoma [MCC],
and ovarian cancer) [4–8]. Indeed, for solid tumors, CD56
serves as a diagnostic biomarker to identify those of neuroen-
docrine origin, including MCC and SCLC [9, 10]. Effective
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treatment options for these two tumor types are limited, par-
ticularly within the context of advanced and/or refractory dis-
ease [11, 12]. CD56 has thus emerged as an attractive molec-
ular candidate for the design of novel, targeted therapeutic
strategies for improving patient outcomes in these indications.
IMGN901 (lorvotuzumab mertansine) is an antibody-
drug conjugate (ADC), consisting of a humanized anti-
CD56 antibody to which the tubulin-binding maytansinoid
DM1 is covalently conjugated via a stable disulfide linker
[13]. IMGN901 targets CD56 at the cell surface and, upon
antigen binding, becomes internalized - resulting in the
intracellular release of DM1 [14], which in turn promotes
disruption of microtubule assembly, G2/metaphase arrest,
and ultimately apoptosis [15–17]. In preclinical models,
IMGN901 has shown high-affinity, antigen-specific bind-
ing and robust antitumor activity in CD56-positive
(CD56+) tumors [18].
A first-in-human, open label phase I/II clinical trial has
previously been conducted in patients with relapsed or refrac-
tory CD56+ SCLC and other CD56+ solid tumors where
IMGN901 was administered weekly for four consecutive
weeks on a six-week cycle [NCT00065429]. The results of
that dose-escalation study revealed that IMGN901 displayed
favorable pharmacokinetics, a manageable safety profile (in-
cluding no cardiac, thyroid or adrenocortical toxicities despite
CD56 expression in those tissues), and encouraging signs of
activity [19, 20]. These findings prompted further evaluation
of IMGN901 in the same target populations using an alterna-
tive dosing schedule. Here we report on an open label, Phase I
trial of IMGN901 dosed on days 1–3 of a 21-day cycle in
patients with CD56+ tumors. This regimen was selected based
on prior human data showing a relatively short half-life for
low doses of IMGN901. This study was undertaken to deter-
mine the tolerability, safety, and maximum tolerated dose
(MTD) of IMGN901 on this schedule. Secondary assessments
included pharmacokinetic profiling and preliminary assess-
ment of clinical activity.
Patients and methods
This was a single-agent, multicenter, open-label, non-random-
ized, Phase I study with expansion at the MTD that involved 9
sites in the United States and the United Kingdom. The study
was conducted in accordance with the US Food and Drug
Administration regulations, the International Conference on
Harmonisation Guidelines for Good Clinical Practice and
the Declaration of Helsinki. The study was compliant with
Institutional Review Board and Independent Ethics
Committee requirements. All patients provided written in-
formed consent in accordance with federal, local and institu-
tional guidelines. This trial was registered at Clinical trials.gov
(NCT00346385).
Eligibility criteria
During dose escalation, enrollment was open to patients who
had histologically or cytologically proven, measurable, re-
lapsed or refractory SCLC, neuroendocrine pulmonary tu-
mors, metastatic MCC or carcinoid tumors, or other CD56+
solid tumors. Tumor CD56 expression was assessed prior to
enrollment or at the earliest opportunity. With the exception of
carcinoid and neuroendocrine tumors (which may not have
been treated with chemotherapy previously), patients who
had received one to three prior therapies were eligible. In the
MTD expansion phase, enrollment was restricted to patients
with relapsed or refractory SCLC, locally advanced or meta-
static MCC, or ovarian cancer. Patients with SCLC who had
received one prior chemotherapy regimen were eligible,
whereas patients with MCC or ovarian cancer may have re-
ceived more than one prior chemotherapy regimen. Patients
with resistant or refractory ovarian cancer must have received
at least one platinum-based regimen.
Eligible patients were required to be ≥18 years of age; have
an Eastern Cooperative Oncology Group (ECOG) perfor-
mance status ≤2; and a life expectancy of at least 3 months.
Adequate hematology laboratory values and organ function
were required. Patients were excluded if they had known hy-
persensitivity to monoclonal antibody therapy; brain metasta-
ses; or a previous malignancy with <3-year disease-free inter-
val other than basal cell carcinoma or carcinoma in situ of the
cervix.
Study design and drug administration
Enrollment of a maximum of 100 patients was planned. In the
dose-escalation phase, patients received IMGN901 intrave-
nously (IV) at 4, 8, 16, 24, 36, 48, 60, 75, or 94 mg/m2 for a
maximum of 4 cycles or until intolerable toxicity, patient with-
drawal or progressive disease (PD). Originally, IMGN901was
to be infused over 1 h; later, the infusion rate was reduced to
40 min. However, because of the onset of Grade 2 or higher
headaches in individuals while being infused at higher doses,
the protocol was amended to establish an infusion rate of
1 mg/min and prophylactic measures for all patients. These
included 8 mg of oral dexamethasone (or equivalent) twice a
day on the day prior to the infusion; 10 mg of IV dexameth-
asone 30 min prior to the infusion; and acetaminophen (500–
650 mg). Patients experiencing objective responses as per
RECIST 1.0 criteria [21], or those with stable disease (SD)
showing clinical benefit were eligible to receive additional
cycles at the same dose as that of their last treatment cycle
until PD or intolerability. In the expansion phase, IMGN901
administration began at the MTD, defined as the highest dose
at which <2 of six patients experienced a dose limiting toxicity
(DLT), defined as grade 4 neutropenia ≥5 days, grade 4 throm-
bocytopenia, neutropenic infection, or any grade 3 or 4 non-
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hematologic toxicity (except nausea, vomiting, diarrhea, and
alopecia).
Safety evaluation
All patients who enrolled and received at least one dose of
study drug underwent safety evaluation (n = 97). AEs were
assessed at each visit and graded according to the National
Cancer Institute Common Terminology Criteria for Adverse
Events Version 4.0.
Efficacy evaluation
Preliminary assessment of efficacy was performed using the
RECIST response criteria version 1.0. A CT scan or MRI was
performed at screening, at the end of treatment Cycles 2 and 4,
at Day 22/early study treatment termination visit, at the 1-
month follow-up visit, and at each short-term follow-up visit
(every 6 weeks after the 1-month follow-up visit until PD or
start of alternate anti-neoplastic therapy). Efficacy parameters
included objective response rate (ORR), duration of response
(DOR), time to progression (TTP), progression free survival
(PFS) and overall survival (OS) for up to 3 years. Patients
were evaluable for efficacy if they had a post-baseline radio-
logic or clinical assessment.
Phamacokinetics evaluation
Blood samples for pharmacokinetic (PK) characterization of
intact conjugate, total huN901 antibody, human anti-human
antibody, and human anti-drug antibody were collected from
all patients at pre-specified time points. PK summary mea-
sures were calculated for each patient. PK analysis was per-
formed using the standard algorithms of the non-
compartmental PK analysis program (201), WinNonlin,
Professional version 6.1.0.173 (Pharsight Corporation,
Mountain View, California).
Statistical methods
Descriptive statistics for continuous variables were sum-
marized using sample size (n), mean, median, standard
deviation, minimum, and/or maximum. Patients who
discontinued IMGN901 and started alternate anti-
neoplastic therapy before documentation of PD were cen-
sored at the time of their last visit prior to initiation of
alternate anti-neoplastic therapy. Patients who died or were
lost to follow-up before documentation of PD or who did
not progress before data cut-off were censored at the time
of their last visit.
Any event with the same onset date as start of study treat-
ment or later was reported as treatment emergent. Time-to-
event variables (DOR, TTP, PFS, and OS) were based on
Kaplan-Meier estimations. Baseline was defined as the last
available assessment prior to Day 1, Cycle 1.
All response-evaluable patients who had a post-baseline
assessment (clinical or radiologic per RECIST 1.0) were in-
cluded in the Clinical Benefit Rate (CBR) analysis (complete
response [CR], partial response [PR] or SD of ≥75 days in
duration). A subset of this evaluable population, excluding
those without post-baseline radiologic assessments, was used
to evaluate the Disease Control Rate (DCR; CR, PR, or SD
≥75 days by radiologic assessment).
Results
Patient characteristics
The study accrued 97 patients, 52 in the dose-escalation phase
and 45 in the expansion phase. In the dose-escalation phase, at
least four patients were treated at each of the first 8 dose levels,
ranging from 4 mg/m2 to 75 mg/m2, and two patients were
treated at the highest dose, 94 mg/m2. In the expansion phase,
the first seven patients were treated at a dose of 75 mg/m2 and
the remaining 38 at 60 mg/m2.
The median age of the patients enrolled in the study was
58 years (range, 18–88) and the distribution of primary
tumor types was SCLC (35.1 %), MCC (23.7 %), neuro-
endocrine carcinoma (15.5 %), and ovarian cancer
(12.4 %) (Table 1). The majority of patients treated at
60 mg/m2 and 75 mg/m2 completed the study (86.4 %
and 90.9 %, respectively), for an overall study completion
rate of 86.6 %. Overall exposure ranged from 1 to 21 cycles
of IMGN901 with total cumulative doses ranging from
22.5 mg to 6680 mg. Twenty-eight percent of the patients
completed 3 or more cycles, with 10.3 % completing at
least 6 cycles of study treatment. Thirteen patients did
not complete Day 22 of cycle 1 as follows: eight patients
withdrew due to disease progression and five withdrew due
to an AE.
Safety and tolerability
Grade 4 fatigue in cycle 1 and Grade 2 peripheral neuropathy
that progressed to Grade 3 in cycle 2 were reported as DLTs in
the 16 mg/m2 (n = 1) and 48 mg/m2 (n = 1) cohorts. At the
75 mg/m2/day dose level, an initial cohort of four patients was
enrolled. One patient experienced a DLT of Grade 4 headache
associated with meningitis-like symptoms, prompting a reduc-
tion in the infusion rate. An additional four patients were treated
with the slowed infusion rate, two of whom developed Grade 2
headaches that in turn prompted the administration of prophy-
lactic steroids. Of a total of seven additional patients in the
steroid pre-treated 75 mg/m2 cohort, one developed neuropathy
in cycle 1 that worsened to a DLT (Grade 3 paresthesia) in cycle
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3. Dose escalation continued to 94 mg/m2 with two patients
who experienced pain-related DLTs on day 8 of cycle 1
(Grade 3 headache, pain, and chest pain in one patient and
Grade 3 myalgia in the other). Therefore, the 75-mg/m2 dose
was declared the MTD. However, because three of the first
seven patients treated at the 75-mg/m2 dose experienced
drug-related serious adverse events (SAEs) (generalized pain
and increased chest pain [n = 1]; fatigue, syncope, Grade 2
neuropathy, and myalgia [n = 1]; and Grade 3 dyspnea,
Grade 2 myalgia, chest pain, and fatigue [n = 1]), a dose of
60 mg/m2/day was explored, and ultimately confirmed as the
recommended phase II dose (RP2D).
Ninety-four patients (96.9 %) reported a treatment-
emergent adverse event (TEAE), the majority of which were
Grade 1 or 2; with nausea (43.3 %), fatigue (39.2 %), and
constipation (37.1 %) being the most commonly reported.
Table 2 summarizes those TEAEs reported for ≥5 % of pa-
tients that were assessed as possibly, probably, or definitely
related (Brelated^) to study treatment (75.3 %). The most com-
mon treatment-related TEAEs were nausea (30.9 %), fatigue
(27.8 %), headache (26.8 %), peripheral neuropathy (17.5 %),
and vomiting (16.5 %).
Seventy-eight patients (80.4 %) reported a Grade 3 or 4
TEAE; 37.1 % were assessed as treatment-related. Overall,
gastrointestinal (25.8 %), metabolism and nutrition (19.6 %),
investigation (18.6 %), and nervous system (15.5 %) disorders
accounted for the highest incidence of Grade 3 or 4 AEs. The
most commonly reported were hyponatremia (8.2 %),
Table 1 Patient demographics and baseline characteristics
Characteristic Dose level (mg/m2)
4–48a (n = 29) 60 (n = 44) 75 (n = 22) 94 (n = 2) Total (n = 97)
Median age (range), years 54.8 (18–77) 60.5 (30–78) 55.0 (29–88) 57.5 (50–65) 58 (18–88)
Gender, n (%)
Male 20 (69.0) 13 (29.5) 7 (31.8) 0 40 (41.2)
Female 9 (31.0) 31 (70.5) 15 (68.2) 2 (100) 57 (58.8)
CD56+ tumor type, n (%)
Carcinoid tumor 1 (3.4) 0 1 (4.5) 0 2 (2.1)
Ewing’s sarcoma 1 (3.4) 0 0 0 1 (1.0)
Lung cancer (undefined) 2 (6.9) 0 0 0 2 (2.1)
Merkel cell carcinoma 2 (6.9) 15 (34.1) 6 (27.3) 0 23 (23.7)
Neoplasmb 1 (3.4) 1 (2.3) 1 (4.5) 0 3 (3.1)
Neuroendocrine carcinoma 7 (24.1) 3 (6.8) 4 (18.2) 1 (50.0) 15 (15.5)
Non-small cell lung cancer 2 (6.9) 0 0 0 2 (2.1)
Ovarian cancer 0 12 (27.3) 0 0 12 (12.4)
Sarcoma 0 0 1 (4.5) 0 1 (1.0)
Small cell lung cancer 12 (41.4) 13 (29.5) 8 (36.4) 1 (50.0) 34 (35.1)
Thyroid cancer 1 (3.4) 0 0 0 1 (1.0)
Vulvar cancer 0 0 1 (4.5) 0 1 (1.0)
Previous treatment, n (%)
Any 29 (100) 44 (100) 22 (100) 2 (100) 97 (100)
Chemotherapy 29 (100) 44 (100) 22 (100) 2 (100) 96 (99.0)
Radiotherapy 20 (69.0) 27 (61.4) 13 (59.1) 1 (50.0) 61 (62.9)
Surgery 13 (44.8) 25 (56.8) 13 (59.1) 2 (100) 53 (54.6)
Otherc 2 (6.9) 4 (9.1) 1 (4.5) 0 7 (7.2)
Patient disposition
Completed Cycle 1 26 (89.7) 38 (86.4) 20 (90.9) 0 84 (86.6)
Did not complete Cycle 1
-Disease deterioration 3 (10.3) 4 (9.1) 1 (4.5) 0 8 (8.2)
-AE/unacceptable toxicity 0 2 (4.5) 1 (4.5) 2 (100) 5 (5.2)
a Combined data; 4 patients received 4 mg/m2 , 4 received 8 mg/m2 , 6 received 16 mg/m2 , 4 received 24 mg/m2 , 4 received 36 mg/m2 , and 7 received
48 mg/m2
bNeoplasm included a right hallus tumor, an unknown primary tumor, and a tumor of the right foot
c Other included hormonal, immunologic or biologic therapies
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dyspnea (8.2 %), and elevated gamma glutamyltransferase
(GGT; 7.2 %). Clinically significant elevations of pancreatic
enzymes (serum amylase, lipase, and/or trypsinogen) were
seen in 16 % of the patients treated at 60 mg/m2 and in one
of four (25 %) patients in the 24-mg/m2 cohort; however, only
two patients experienced an AE of pancreatitis.
SAEs were reported for 53 patients (54.6 %) and treatment-
related SAEs were experienced by 15 patients (15.5 %). These
Table 2 Related treatment-
emergent adverse events reported
in ≥5 % of patients (all grades)
Related TEAEs, n (%)a Dose level (mg/m2)
4–48b (n = 29) 60 (n = 44) 75 (n = 22) 94 (n = 2) Total (n = 97)
Any AE 16 (55.2) 36 (81.8) 19 (86.4) 2 (100) 73 (75.3)
Blood and lymphatic system 1 (3.4) 3 (6.8) 3 (13.6) 0 7 (7.2)
Gastrointestinal disorders 9 (31.0) 27 (61.4) 14 (63.6) 2 (100) 52 (53.6)
Constipation 2 (6.9) 4 (9.1) 2 (9.1) 0 8 (8.2)
Diarrhea 1 (3.4) 8 (18.2) 3 (13.6) 1 (50.0) 13 (13.4)
Nausea 6 (20.7) 18 (40.9) 6 (27.3) 0 30 (30.9)
Vomiting 6 (20.7) 7 (15.9) 3 (13.6) 0 16 (16.5)
General/IV site disorders 8 (27.6) 20 (45.5) 11 (50.0) 2 (100) 41 (42.3)
Chest pain 0 0 4 (18.2) 1 (50.0) 5 (5.2)
Fatigue 4 (13.8) 14 (31.8) 8 (36.4) 1 (50.0) 27 (27.8)
Pain 0 5 (11.4) 1 (4.5) 1 (50.0) 7 (7.2)
Infections/infestations 1 (3.4) 5 (11.4) 1 (4.5) 0 7 (7.2)
Investigations 1 (3.4) 19 (43.2) 12 (54.5) 1 (50.0) 33 (34.0)
ALT 0 9 (20.5) 3 (13.6) 1 (50.0) 13 (13.4)
AST 0 9 (20.5) 6 (27.3) 1 (50.0) 16 (16.5)
GGT 0 6 (13.6) 4 (18.2) 1 (50.0) 11 (11.3)
Hemoglobin decreased 0 4 (9.1) 1 (4.5) 0 5 (5.2)
Lipase increased 0 5 (11.4) 0 0 5 (5.2)
Metabolism/nutrition disorders 2 (6.9) 13 (29.5) 5 (22.7) 0 20 (20.6)
Appetite decreased 1 (3.4) 3 (6.8) 5 (22.7) 0 9 (9.3)
Hypokalemia 1 (3.4) 5 (11.4) 1 (4.5) 0 7 (7.2)
Musculoskeletal/connective
tissue
1 (3.4) 14 (31.8) 11 (50.0) 1 (50.0) 27 (27.8)
Arthralgia 0 4 (9.1) 3 (13.6) 0 7 (7.2)
Back pain 0 2 (4.5) 2 (9.1) 1 (50.0) 5 (5.2)
Myalgia 1 (3.4) 5 (11.4) 5 (22.7) 1 (50.0) 12 (12.4)
Pain in extremity 0 1 (2.3) 7 (31.8) 0 8 (8.2)
Nervous system disorder 11 (37.9) 26 (59.1) 15 (68.2) 1 (50.0) 53 (54.6)
Dysgeusia 1 (3.4) 4 (9.1) 1 (4.5) 0 6 (6.2)
Headache 6 (20.7) 11 (25.0) 8 (36.4) 1 (50.0) 26 (26.8)
Lethargy 3 (10.3) 1 (2.3) 1 (4.5) 0 5 (5.2)
Paresthesia 0 2 (4.5) 4 (18.2) 0 6 (6.2)
Peripheral neuropathy 1 (3.4) 10 (22.7) 6 (27.3) 0 17 (17.5)
Peripheral sensory neuropathy 2 (6.9) 6 (13.6) 6 (27.3) 0 14 (14.4)
Psychiatric disorders 0 6 (13.6) 1 (4.5) 0 7 (7.2)
Respiratory/thoracic/mediastinal 2 (6.9) 6 (13.6) 3 (13.6) 1 (50.0) 12 (12.4)
Skin/subcutaneous tissue 3 (10.3) 6 (13.6) 0 1 (50.0) 10 (10.3)
Vascular disorders 2 (6.9) 5 (11.4) 1 (4.5) 0 8 (8.2)
a Treatment-emergent AEs are AEs with an onset date on or after the date of first dosing with IMGN901;
treatment-related AEs are events with the maximum relationship to IMGN901 treatment as determined by the
Investigator’s assessment of possibly, probably, or definitely related
b Combined data; 4 patients received 4 mg/m2 , 4 received 8 mg/m2 , 6 received 16 mg/m2 , 4 received 24 mg/m2 ,
4 received 36 mg/m2 , and 7 received 48 mg/m2
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included constipation (3.1%); headache (3.1%); pain, fatigue,
pain in extremity, and chest pain (2.1 %); and abdominal pain
and fever (1.0 %). One patient treated at 60 mg/m2 experi-
enced reversible posterior leukoencephalopathy syndrome
with cortical blindness [22]. Twelve patients experienced a
SAE with an outcome of death. However, only one of these
SAEs (bronchopneumonia), which occurred in a patient treat-
ed at 75-mg/m2, was judged to be related to study treatment.
Efficacy
Clinical benefit was observed in 25.5 % of all patients, with a
CBR of 27.3 % in the cohort of individuals treated at the
60 mg/m2 dose level (Table 3). These values included SD
lasting ≥75 days being seen in 25 % of patients who received
a dose of 60 mg/m2 or higher (n = 68). Four patients met
RECIST criteria for objective responses (Fig. 1 and Table 4)
as follows: one patient with MCC who had received
IMGN901 at 36 mg/m2 had a confirmed CR; a second MCC
patient treated at 60 mg/m2 had a confirmed PR that
progressed to clinical CR but refused further CT assessment
and, therefore, could be evaluated only by clinical assessment;
and two patients, one with MCC (60 mg/m2) and another with
SCLC (75mg/m2) had unconfirmed PRs. Overall disease con-
trol rates (DCR values) were 18.2 % for all evaluable patients
and 22.5 % for those treated at 60 mg/m2.
These findings revealed that the most notable activity was
observed in patients with metastatic MCC (n = 23), with
thirteen percent overall demonstrating responses to treatment
(Table 5). One patient received a total of 6 cycles of treatment
with IMGN901 at 36 mg/m2 and achieved a PR after cycle 1
and a CR by cycle 3. The patient remained in complete remis-
sion for nearly 6 years until dying from non-small cell lung
cancer (NSCLC). Another patient had a PR after cycle 1 of
treatment with IMGN901 at 60 mg/m2 (65 % reduction in
target skin lesions), but developed reversible posterior
leukoencephalopathy syndrome and was discontinued. This
patient achieved a clinical CR with resolution of all skin le-
sions 2 years after treatment with a single course of IMGN901
and was still alive with no signs of disease progression at the
last follow-up visit (~2.8 years). A third patient, who present-
ed with widespread metastatic disease at baseline, developed
PD after cycle 2 of treatment. Interestingly, whole body PET
CT scan performed 8 months after study discontinuation re-
vealed no evidence of FDG-avid disease. Subsequently, he
experienced waxing and waning low-volume disease (<1 cm
diameter of some lesions), but the patient was alive with no
signs of PD 2.4 years after receiving the first dose of
IMGN901 and without having received any additional thera-
py. Two patients achieved clinically relevant SD; one of them
remained on study for 10 cycles, whereas the other received
21 cycles of treatment and was discontinued due to an AE of
ataxia.
Clinical activity was also observed in additional tumor
types. The CBR for patients with ovarian cancer (n = 12)
was 33.3 %. One patient in this group received 12 cycles of
Table 3 Efficacy parameters by dose level
Efficacy Parameters Dose level (mg/m2)a
4–48a (n = 27) 60 (n = 44) 75 (n = 21) 94 (n = 2) Total (n = 94)
Clinical benefitb
No. patients with clinical benefit 5 12 6 1 24
Clinical benefit ratec 18.5 % 27.3 % 28.6 % 50 % 25.5 %
Time to progressiond
No. patients who progressed/died 24 40 17 2 83
No. patients censored 3 4 4 0 11
Median TTP [95 % CI], months 1.4 [0.7,1.9] 1.3 [1.2,1.6] 2.1 2.0 (1.0,3.3] 2.1 [1.2,1.5]
Progression-free survivale
No. patients who progressed/died 25 41 17 2 85
No. patients censored 2 3 4 0 9
Median PFS [95 % CI], months 1.4 [0.7,1.9] 1.3 [1.2,1.6] 2.1 2.0 [1.0,3.3] 2.1 [1.2,1.5]
a Combined data; 4 patients received 4 mg/m2 , 4 received 8 mg/m2 , 6 received 16 mg/m2 , 4 received 24 mg/m2 , 4 received 36 mg/m2 , and 7 received
48 mg/m2
b Clinical benefit is defined as Time to Progression ≥75 days or an Objective Response (radiologic criteria)
c Clinical benefit rate is the number of patients with a clinical benefit ÷ number of patients in the evaluable population × 100
d Time to progression in days was calculated from the date of first dose of IMGN901 until the date of progressive disease
e Progression-free survival is defined as the time (in days) from the date of enrollment to the date of documented disease progression or death from any
cause. Progressive disease was defined according to the RECIST 1.0 criteria. [New Guidelines 2000] If a patient had not progressed or died, the patient
was censored on the date of the last disease assessment
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therapy with IMGN901 before developing PD and was alive
at 1.9 years after her first dose of IMGN901. Patients with
SCLC demonstrated a CBR of 21.2 % (n = 33), with one
patient achieving an unconfirmed PR and six patients
experiencing SD.
The median PFS and TTP were identical for both the over-
all population (2.1 months; CI = 1.2, 1.5 months) and for the
subset of patients treated with 60 mg/m2 of IMGN901
(1.3 months; CI = 1.2, 1.6 months) (Table 2). Median OS for
all patients was 9.2 months (CI = 5.7, 13.2 months), whereas
median OS for patients treated at 60 mg/m2 was 8.1 months
(CI = 5.5, 14.3 months).
Pharmacokinetics
The maximum plasma concentration (Cmax) and area under
the concentration curve (AUC0-∞) of IMGN901 generally in-
creased with increasing dose (Fig. 2a, 2b). These parameters
also increased with subsequent treatments within a cycle
(Cmax shown in Fig. 2c). At the 60 mg/m
2 dose, a consistent
Fig. 1 Relative change from baseline in target lesion size (at best tumor
response). The maximum percent change in the sum of target lesions is
displayed graphically, by histological subtype, for the 77 patients in the
subset of efficacy evaluable population (n = 88) who had measurable
disease and met RECIST criteria for evaluable post-baseline imaging
measurement. SCLC, small cell lung cancer; MCC, Merkel cell
carcinoma
Table 4 Patients with PR or CR by radiologic and clinical assessments
Primary
tumor
IHC
scorea
Dose level
(mg/m2)
Period Best Response Confirmedb DOR
(months)
TTP
(months)
PFS
(months)
OS
(months)
MCC 3 + homo 36 Cycle 3 CR Yes 69.4c 70c 75.2 75.2
SCLC TNA 75 Cycle 1 PR No 1.4 1.9 1.9 2.1c
MCC 3 + homo 60 1 month FU Radiologic PR followed by a clinical CR Yes 32.7c 34.1 34.1c 34.1
MCC TNA 60 Cycle 1 PR No 1.5 2.8 2.8 8.1
CR complete response,DOR duration of response, PFS progression-free survival, IHC immunohistochemistry,OS overall survival, PR partial response,
TNA tissue not available, TTP time to progression
a Visual Scoring: staining intensity in test samples was scored 0–3 (0 = no staining, 1 = weak, 2 =moderate, 3 = strong) and% uniformity (focal = <25%;
heterogeneous =25–75 %; and homogeneous = >75 %)
b Confirmed by a repeat assessment performed prior to every other cycle (every 6 weeks) or until tumor progression
c Observation was censored
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elevation in the median Cmax (about 1.5-fold on day 3) was
observed. The half-life of IMGN901 at the 60 mg/m2 dose
was approximately 30 to 40 h following Day 3 of cycle 1.
The concentration-time profiles for total huN901 antibody
were similar to those of IMGN901 (data not shown). Total
huN901 antibody had a slightly longer elimination half-life
than IMGN901 at doses ≥60 mg/m2.
Discussion
In this study, we evaluated the safety, tolerability, pharmaco-
kinetics and preliminary efficacy of single agent IMGN901
administered on Days 1–3 of a 21-day cycle to patients with
CD56-positive solid tumors. Ninety-seven patients were ac-
crued. Patients in the dose-escalation phase received
Table 5 Locally advanced and
metastatic Merkel cell carcinoma
patients
Age/Gender IHC scorea No. cycles Best Response Reason for discontinuation
68/M TNA 2 PD (cycle 2) PD
67/F 3 + homo 1 PD (cycle 1) PD
55/F 3 + homo 6 (36 mg/m2) CR (cycle 3) Completed study
77/M 3 + homo 1 PD (cycle 1) PD
67/F 3 + homo 1 (60 mg/m2) PR/clinical CR AE
50/M TNA 2 PD (cycle 2) AE
59/M 3 + homo 4 PD (cycle 4) PD
62/M 3 + homo 1 PD (cycle 1) PD
55/F 3 + homo 2 PD (cycle 2) PD
45/M 3 + homo 10 (60 mg/m2) PD (cycle 8) Withdrawal of consent
78/F 3 + homo 2 SD AE
67/F 3 + homo 4 PD (cycle 4) PD
62/F 3 + homo 21 (60 mg/m2) SD AE
56/M 3 + homo 2 PD (cycle 2) PD
77/F 3 + homo 2 PD (cycle 2) PD
68/F 2 + hetero 2 PD (cycle 2) PD
78/M 2 + hetero 2 PD (cycle 2) AE
75/M TNA 2 PD (cycle 2) PD
59/M 3 + homo 2 PD (cycle 2) PD
67/F TNA 2 PD (cycle 2) PD
53/M 2 + homo 2 PD (cycle 2) PD
54/F 3 + homo 2 PD (cycle 2) PD
68/M TNA 1 PR/PD (after cycle 1) AE
AE adverse event, CR complete response, IHC immunohistochemistry, PD progressive disease, PR partial re-
sponse, SD stable disease, TNA tissue not available
a Visual Scoring: staining intensity in test samples was scored 0–3 (0 = no staining, 1 = weak, 2 = moderate,
3 = strong) and % uniformity (focal = <25 %; heterogeneous =25–75 %; and homogeneous = >75 %)
Fig. 2 Pharmacokinetics. a Plasma concentration (mean ± SD) of
IMGN901 over time of patients given doses at 4, 8, 16, 24, 36, 48, 60,
75, and 94 mg/m2 (LLQ = lower limit of quantitation). b Cmax of
IMGN901 (− −∗− −) and area under the concentration curve (AUC0-∞)
(—⋄—) of patients given doses at 4, 8, 16, 24, 36, 48, 60, and 75 mg/m2.
c Maximum plasma concentration (Cmax) of IMGN901 with median
(——) for end of infusion at the first dose of cycle 1, the third dose of
cycle 1, and the first dose of cycle 2 of patients given doses at 60 mg/m2
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IMGN901 at doses ranging from 4 to 94 mg/m2. The MTD
was declared at 75 mg/m2 and the first seven patients enrolled
into the dose-expansion phase were treated at that dose level.
During drug administration, however, three patients experi-
enced dose-limiting headache with or without meningitis-
like symptoms. These events prompted the implementation
of a slower infusion rate and prophylactic low-dose steroids
and acetominophen, which reduced the incidence and severity
of these symptoms. Similar toxicity was observed in the first-
in-human study, with symptoms developing within 6 to 8 h
post-infusion and resolving within 1 to 3 days [19, 23, 24].
Despite these measures, 3 of 7 patients experienced drug-
related SAEs at 75 mg/m2, thus the RP2D was determined
to be 60 mg/m2.
Preliminary evidence of antitumor activity of IMGN901
was noted in several CD56+ tumor types. Of the 94 patients
in the efficacy evaluable population, 25.5 % experienced clin-
ical benefit. Patients treated with 60 mg/m2 experienced the
highest CBR (27.3 %). Four patients, three of whom were
diagnosed with MCC, had objective responses. While the
ORR was modest, it should be noted that all patients had
previously been treated with other therapies and almost half
(49 %) had received two or more prior lines of treatment.
Themost interesting signals of clinical activity were seen in
patients withmetastaticMCC, a rare and aggressive cutaneous
malignancy of neuroendocrine origin. Surgical excision of the
primary tumor is the first line of treatment; however, MCC has
a high propensity for local recurrence as well as regional and
distant metastases [25, 26]. Current therapies have demon-
strated no survival benefit for patients with distal metastatic
disease [27], and for this patient population, treatment is lim-
ited to palliative care [28]. As noted above, three objective and
durable responses and an overall CBR of 21.7 % were ob-
served among the 23 patients with metastatic MCC recruited
to the study. Together with preliminary signs of efficacy in
SCLC and ovarian cancer patients, these results provide en-
couraging evidence of single-agent IMGN901 activity.
Analysis of CD56 expression demonstrated strong expres-
sion in the majority of the tumors. Despite this, not all patients
derived meaningful clinical benefit. A potential explanation
for this may involve acquired resistance to the microtubule-
targeting payload among the heavily pre-treated patients en-
rolled in this study. For example, SCLC is usually responsive
to initial platinum-based chemotherapy, but subsequent che-
motherapy rarely results in response and shows only modest
improvements in survival [29]. Furthermore, preclinical evi-
dence suggests that induced resistance to cisplatin can render
SCLC cells cross-resistant to the microtubule-disrupting vinca
alkaloids [30]. Other factors that may contribute to lack of
response in some patients include heterogeneous CD56 ex-
pression within a tumor, or varying rates of ADC internaliza-
tion. The half-life of IMGN901 is relatively short compared
with that of other humanized IgG1 antibodies; this can be
explained, at least in part, by high antigen-mediated clearance
due to CD56 expression on a variety of normal tissues, in
particular highly abundant NK cells. This may serve to restrict
IMGN901 exposure, which, in turn, may limit activity to tu-
mors exquisitely sensitive to the maytansinoid payload.
In conclusion, IMGN901 administered IV at a dose of
60 mg/m2 on three consecutive days every 3 weeks exhibited
acceptable safety and tolerability. Objective, durable responses
in a number of patients with MCC, and durable SD observed in
several previously treated patients with relapsed advanced-
stage CD56+ cancers, are encouraging signs of single-agent
IMGN901 activity. The clinical evaluation of IMGN901 is on-
going, with two Phase II studies, one in CD56-expressing he-
matological malignancies [NCT02420873] and the other in pe-
diatric neuroendocrine-derived tumors [NCT02452554], hav-
ing recently been initiated.
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